HRMY vs AUPH
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
HRMY · Harmony Biosciences$32.59 ▼ 1.18%
AUPH · Aurinia Pharmaceuticals$14.70 ▼ 1.28%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- HRMY -7.6%
- AUPH -8.8%
Head to head
| Metric | HRMY | AUPH |
|---|---|---|
| Price | $32.59 | $14.70 |
| Change today | ▼ 1.18% | ▼ 1.28% |
| Market cap | $1.91B | $1.97B |
| Return, 3 months | -15.4% | -11.3% |
| Return, year to date | -12.9% | -7.8% |
| Return, 1 year | -5.0% | -6.3% |
| P/E (TTM) | 10.8 | 6.4 |
| P/B | 1.8 | 3.0 |
| P/E percentile vs own 5y | 17th | 67th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +12.3% | +13.9% |
| Net profit growth (YoY) | -5.2% | +0.5% |
| Gross margin | 74.0% | 90.6% |
| Operating margin | 22.2% | 48.6% |
| Net margin | 18.1% | 97.7% |
| Return on equity | 18.7% | 61.4% |
| Analyst target vs. price | +45.8% | +29.3% |
| Analyst buy share | 63% | 67% |
| RSI (14) | 32 | 30 |
| 30-day volatility | 42.9% | 31.7% |
| Max drawdown, 1 year | -34.5% | -21.8% |
| Trend read | Strong downtrend | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- AUPH is the largest of the group by market value.
- HRMY has returned the most over the past year.
- AUPH carries the lowest trailing P/E.
- AUPH is growing revenue fastest.
- AUPH keeps the most profit per dollar of sales.
- AUPH has been the calmest stock over the last 30 days.